Analysts Expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Will Post Earnings of -$0.06 Per Share

Equities analysts forecast that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will post ($0.06) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for BioDelivery Sciences International’s earnings, with estimates ranging from ($0.25) to ($0.01). BioDelivery Sciences International posted earnings of ($0.16) per share during the same quarter last year, which suggests a positive year over year growth rate of 62.5%. The business is scheduled to issue its next quarterly earnings report on Thursday, August 8th.

On average, analysts expect that BioDelivery Sciences International will report full year earnings of ($0.14) per share for the current fiscal year, with EPS estimates ranging from ($0.42) to ($0.05). For the next fiscal year, analysts anticipate that the firm will report earnings of $0.25 per share, with EPS estimates ranging from $0.09 to $0.46. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover BioDelivery Sciences International.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The business had revenue of $19.77 million for the quarter, compared to analyst estimates of $19.60 million. BioDelivery Sciences International had a negative net margin of 42.09% and a negative return on equity of 43.40%.

BDSI has been the topic of a number of research reports. Cantor Fitzgerald set a $8.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Friday, April 26th. SunTrust Banks initiated coverage on shares of BioDelivery Sciences International in a research report on Tuesday, March 19th. They set a “buy” rating and a $7.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of BioDelivery Sciences International in a research report on Friday, March 15th. BidaskClub lowered shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Friday, May 17th. Finally, Zacks Investment Research lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $6.20.

In related news, Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $4.77, for a total value of $38,160.00. Following the transaction, the director now directly owns 598,254 shares in the company, valued at approximately $2,853,671.58. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Healthcare Master Fun Broadfin sold 2,000,000 shares of BioDelivery Sciences International stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $5.00, for a total transaction of $10,000,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,339,037 shares of company stock worth $21,313,438. 13.26% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of the stock. Advisor Group Inc. grew its position in BioDelivery Sciences International by 56.3% in the 4th quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock valued at $40,000 after buying an additional 3,943 shares during the last quarter. Geode Capital Management LLC grew its position in BioDelivery Sciences International by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 517,620 shares of the specialty pharmaceutical company’s stock valued at $1,915,000 after buying an additional 5,628 shares during the last quarter. Raymond James & Associates grew its position in BioDelivery Sciences International by 14.9% in the 4th quarter. Raymond James & Associates now owns 46,211 shares of the specialty pharmaceutical company’s stock valued at $171,000 after buying an additional 6,000 shares during the last quarter. Janney Montgomery Scott LLC grew its position in BioDelivery Sciences International by 23.3% in the 1st quarter. Janney Montgomery Scott LLC now owns 45,800 shares of the specialty pharmaceutical company’s stock valued at $243,000 after buying an additional 8,642 shares during the last quarter. Finally, First Allied Advisory Services Inc. acquired a new stake in BioDelivery Sciences International in the first quarter valued at $58,000. Hedge funds and other institutional investors own 56.79% of the company’s stock.

Shares of BDSI opened at $4.40 on Wednesday. The company has a debt-to-equity ratio of 1.90, a current ratio of 2.88 and a quick ratio of 2.57. BioDelivery Sciences International has a 12-month low of $2.35 and a 12-month high of $5.37.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

See Also: The benefits and drawbacks of dollar cost averaging

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.